Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaao1641. doi: 10.1126/scitranslmed.aao1641.

PMID:
29298865
2.

Tudor Domain Containing Protein 3 Promotes Tumorigenesis and Invasive Capacity of Breast Cancer Cells.

Morettin A, Paris G, Bouzid Y, Baldwin RM, Falls TJ, Bell JC, Côté J.

Sci Rep. 2017 Jul 11;7(1):5153. doi: 10.1038/s41598-017-04955-4.

3.

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC.

Mol Ther Oncolytics. 2016 Nov 16;3:16027. eCollection 2016.

4.

Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer.

Wong CM, Nash LA, Del Papa J, Poulin KL, Falls T, Bell JC, Parks RJ.

Cancer Gene Ther. 2016 Oct;23(10):355-364. doi: 10.1038/cgt.2016.41. Epub 2016 Oct 14.

5.

Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors.

Wang J, Arulanandam R, Wassenaar R, Falls T, Petryk J, Paget J, Garson K, Cemeus C, Vanderhyden BC, Wells RG, Bell JC, Le Boeuf F.

J Nucl Med. 2017 Feb;58(2):221-227. doi: 10.2967/jnumed.116.180463. Epub 2016 Sep 15.

6.

Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.

Bourgeois-Daigneault MC, St-Germain LE, Roy DG, Pelin A, Aitken AS, Arulanandam R, Falls T, Garcia V, Diallo JS, Bell JC.

Breast Cancer Res. 2016 Aug 8;18(1):83. doi: 10.1186/s13058-016-0744-y.

7.

Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity.

Bourgeois-Daigneault MC, Roy DG, Falls T, Twumasi-Boateng K, St-Germain LE, Marguerie M, Garcia V, Selman M, Jennings VA, Pettigrew J, Amos S, Diallo JS, Nelson B, Bell JC.

Mol Ther Oncolytics. 2016 Feb 17;3:16001. doi: 10.1038/mto.2016.1. eCollection 2016.

8.

Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

Falls T, Roy DG, Bell JC, Bourgeois-Daigneault MC.

ILAR J. 2016;57(1):73-85. doi: 10.1093/ilar/ilv048.

9.

Adenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of Cancer.

Wong CM, Poulin KL, Tong G, Christou C, Kennedy MA, Falls T, Bell JC, Parks RJ.

PLoS One. 2016 Mar 17;11(3):e0151516. doi: 10.1371/journal.pone.0151516. eCollection 2016.

10.

Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy.

Roy DG, Power AT, Bourgeois-Daigneault MC, Falls T, Ferreira L, Stern A, Tanese de Souza C, McCart JA, Stojdl DF, Lichty BD, Atkins H, Auer RC, Bell JC, Le Boeuf F.

J Control Release. 2015 Dec 28;220(Pt A):210-221. doi: 10.1016/j.jconrel.2015.10.030. Epub 2015 Oct 19.

PMID:
26482080
11.

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, Howe GA, Bourgeois-Daigneault MC, Conrad DP, Daneshmand M, Breitbach CJ, Kirn DH, Raptis L, Sad S, Atkins H, Huh MS, Diallo JS, Lichty BD, Ilkow CS, Le Boeuf F, Addison CL, McCart JA, Bell JC.

Cancer Cell. 2015 Aug 10;28(2):210-24. doi: 10.1016/j.ccell.2015.06.009. Epub 2015 Jul 23.

12.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, Zhang J, Le Boeuf F, Arulanandam R, Stubbert L, Sampath P, Thorne SH, Paramanthan P, Chatterjee A, Strieter RM, Burdick M, Addison CL, Stojdl DF, Atkins HL, Auer RC, Diallo JS, Lichty BD, Bell JC.

Nat Med. 2015 May;21(5):530-6. doi: 10.1038/nm.3848. Epub 2015 Apr 20.

PMID:
25894825
13.

Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing.

Arulanandam R, Batenchuk C, Varette O, Zakaria C, Garcia V, Forbes NE, Davis C, Krishnan R, Karmacharya R, Cox J, Sinha A, Babawy A, Waite K, Weinstein E, Falls T, Chen A, Hamill J, De Silva N, Conrad DP, Atkins H, Garson K, Ilkow C, Kærn M, Vanderhyden B, Sonenberg N, Alain T, Le Boeuf F, Bell JC, Diallo JS.

Nat Commun. 2015 Mar 30;6:6410. doi: 10.1038/ncomms7410.

PMID:
25817275
14.

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Evgin L, Acuna SA, Tanese de Souza C, Marguerie M, Lemay CG, Ilkow CS, Findlay CS, Falls T, Parato KA, Hanwell D, Goldstein A, Lopez R, Lafrance S, Breitbach CJ, Kirn D, Atkins H, Auer RC, Thurman JM, Stahl GL, Lambris JD, Bell JC, McCart JA.

Mol Ther. 2015 Jun;23(6):1066-1076. doi: 10.1038/mt.2015.49. Epub 2015 Mar 25.

15.

Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression.

Baldwin RM, Haghandish N, Daneshmand M, Amin S, Paris G, Falls TJ, Bell JC, Islam S, Côté J.

Oncotarget. 2015 Feb 20;6(5):3013-32.

16.

Decreasing incidence of femoral neck fractures in the Medicare population.

MacKinlay K, Falls T, Lau E, Day J, Kurtz S, Ong K, Malkani A.

Orthopedics. 2014 Oct;37(10):e917-24. doi: 10.3928/01477447-20140924-60.

PMID:
25275981
17.

Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.

Ruotsalainen JJ, Kaikkonen MU, Niittykoski M, Martikainen MW, Lemay CG, Cox J, De Silva NS, Kus A, Falls TJ, Diallo JS, Le Boeuf F, Bell JC, Ylä-Herttuala S, Hinkkanen AE, Vähä-Koskela MJ.

Gene Ther. 2015 Jan;22(1):65-75. doi: 10.1038/gt.2014.83. Epub 2014 Sep 18.

PMID:
25231172
18.

Decreased blood transfusion following revision total knee arthroplasty using tranexamic acid.

Samujh C, Falls TD, Wessel R, Smith L, Malkani AL.

J Arthroplasty. 2014 Sep;29(9 Suppl):182-5. doi: 10.1016/j.arth.2014.03.047. Epub 2014 May 24.

PMID:
25015759
19.

Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.

Muik A, Stubbert LJ, Jahedi RZ, Geiβ Y, Kimpel J, Dold C, Tober R, Volk A, Klein S, Dietrich U, Yadollahi B, Falls T, Miletic H, Stojdl D, Bell JC, von Laer D.

Cancer Res. 2014 Jul 1;74(13):3567-78. doi: 10.1158/0008-5472.CAN-13-3306. Epub 2014 May 8.

20.

Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity.

Batenchuk C, Le Boeuf F, Stubbert L, Falls T, Atkins HL, Bell JC, Conrad DP.

Blood Cancer J. 2014 Apr 11;4:e201. doi: 10.1038/bcj.2014.21. No abstract available.

21.

Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

Zhang J, Tai LH, Ilkow CS, Alkayyal AA, Ananth AA, de Souza CT, Wang J, Sahi S, Ly L, Lefebvre C, Falls TJ, Stephenson KB, Mahmoud AB, Makrigiannis AP, Lichty BD, Bell JC, Stojdl DF, Auer RC.

Mol Ther. 2014 Jul;22(7):1320-1332. doi: 10.1038/mt.2014.60. Epub 2014 Apr 3.

22.

Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.

Cronin M, Le Boeuf F, Murphy C, Roy DG, Falls T, Bell JC, Tangney M.

Mol Ther. 2014 Jun;22(6):1188-1197. doi: 10.1038/mt.2014.23. Epub 2014 Feb 26.

23.

Double-stranded RNA-dependent protein kinase deficiency protects the heart from systolic overload-induced congestive heart failure.

Wang H, Xu X, Fassett J, Kwak D, Liu X, Hu X, Falls TJ, Bell JC, Li H, Bitterman P, Bache RJ, Chen Y.

Circulation. 2014 Apr 1;129(13):1397-406. doi: 10.1161/CIRCULATIONAHA.113.002209. Epub 2014 Jan 24.

24.

Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity.

Batenchuk C, Le Boeuf F, Stubbert L, Falls T, Atkins HL, Bell JC, Conrad DP.

Blood Cancer J. 2013 Jul 12;3:e123. doi: 10.1038/bcj.2013.23.

25.

Model-based rational design of an oncolytic virus with improved therapeutic potential.

Le Bœuf F, Batenchuk C, Vähä-Koskela M, Breton S, Roy D, Lemay C, Cox J, Abdelbary H, Falls T, Waghray G, Atkins H, Stojdl D, Diallo JS, Kærn M, Bell JC.

Nat Commun. 2013;4:1974. doi: 10.1038/ncomms2974.

PMID:
23764612
26.

Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia.

Conrad DP, Tsang J, Maclean M, Diallo JS, Le Boeuf F, Lemay CG, Falls TJ, Parato KA, Bell JC, Atkins HL.

Clin Cancer Res. 2013 Jul 15;19(14):3832-43. doi: 10.1158/1078-0432.CCR-12-3199. Epub 2013 May 28.

27.

Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma.

Vähä-Koskela MJ, Le Boeuf F, Lemay C, De Silva N, Diallo JS, Cox J, Becker M, Choi Y, Ananth A, Sellers C, Breton S, Roy D, Falls T, Brun J, Hemminki A, Hinkkanen A, Bell JC.

J Virol. 2013 Feb;87(4):2363-6. doi: 10.1128/JVI.01609-12. Epub 2012 Dec 5.

28.

Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model.

Seth R, Tai LH, Falls T, de Souza CT, Bell JC, Carrier M, Atkins H, Boushey R, Auer RA.

Ann Surg. 2013 Jul;258(1):158-68. doi: 10.1097/SLA.0b013e31826fcbdb.

PMID:
23108132
29.

Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells.

Tai LH, de Souza CT, Bélanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Ananth AA, Lam T, Breitbach CJ, Falls TJ, Kirn DH, Bell JC, Makrigiannis AP, Auer RA.

Cancer Res. 2013 Jan 1;73(1):97-107. doi: 10.1158/0008-5472.CAN-12-1993. Epub 2012 Oct 22.

30.

Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

Lemay CG, Rintoul JL, Kus A, Paterson JM, Garcia V, Falls TJ, Ferreira L, Bridle BW, Conrad DP, Tang VA, Diallo JS, Arulanandam R, Le Boeuf F, Garson K, Vanderhyden BC, Stojdl DF, Lichty BD, Atkins HL, Parato KA, Bell JC, Auer RC.

Mol Ther. 2012 Sep;20(9):1791-9. doi: 10.1038/mt.2012.128. Epub 2012 Jul 3.

31.

Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum.

Brun J, Mahoney DJ, Le Boeuf F, Lefebvre C, Sanaei CA, Falls T, Mccart JA, Stojdl DF.

Int J Cancer. 2013 Feb 1;132(3):726-31. doi: 10.1002/ijc.27695. Epub 2012 Sep 28.

32.

Talking turkey: fracture care and smoking cessation.

Roberts CS, Falls TD.

Injury. 2012 Mar;43(3):257-8. doi: 10.1016/j.injury.2012.01.018. No abstract available.

PMID:
22341240
33.

ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.

Rintoul JL, Lemay CG, Tai LH, Stanford MM, Falls TJ, de Souza CT, Bridle BW, Daneshmand M, Ohashi PS, Wan Y, Lichty BD, Mercer AA, Auer RC, Atkins HL, Bell JC.

Mol Ther. 2012 Jun;20(6):1148-57. doi: 10.1038/mt.2011.301. Epub 2012 Jan 24.

34.

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC.

Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20.

35.

Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death.

Mahoney DJ, Lefebvre C, Allan K, Brun J, Sanaei CA, Baird S, Pearce N, Grönberg S, Wilson B, Prakesh M, Aman A, Isaac M, Mamai A, Uehling D, Al-Awar R, Falls T, Alain T, Stojdl DF.

Cancer Cell. 2011 Oct 18;20(4):443-56. doi: 10.1016/j.ccr.2011.09.005.

36.

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, Lee YK, Oh SY, Woo HY, Parato K, Rintoul J, Falls T, Hickman T, Rhee BG, Bell JC, Kirn DH, Hwang TH.

Mol Ther. 2011 Jun;19(6):1170-9. doi: 10.1038/mt.2011.39. Epub 2011 Mar 22.

37.

Targeting tumor vasculature with an oncolytic virus.

Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, Sun YY, Roy DG, Rintoul JL, Daneshmand M, Parato K, Stanford MM, Lichty BD, Fenster A, Kirn D, Atkins H, Bell JC.

Mol Ther. 2011 May;19(5):886-94. doi: 10.1038/mt.2011.26. Epub 2011 Mar 1.

38.

Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.

MacTavish H, Diallo JS, Huang B, Stanford M, Le Boeuf F, De Silva N, Cox J, Simmons JG, Guimond T, Falls T, McCart JA, Atkins H, Breitbach C, Kirn D, Thorne S, Bell JC.

PLoS One. 2010 Dec 30;5(12):e14462. doi: 10.1371/journal.pone.0014462.

39.

Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.

Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H, Bell JC, McCart JA, Mahoney D, Stojdl DF.

Mol Ther. 2010 Aug;18(8):1440-9. doi: 10.1038/mt.2010.103. Epub 2010 Jun 15.

40.

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Diallo JS, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, MacTavish H, Waite K, Falls T, Wang J, Brown R, Blanchard JE, Brown ED, Kirn DH, Hiscott J, Atkins H, Lichty BD, Bell JC.

Mol Ther. 2010 Jun;18(6):1123-9. doi: 10.1038/mt.2010.67. Epub 2010 Apr 13.

41.

Synergistic interaction between oncolytic viruses augments tumor killing.

Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, Parato K, Atkins H, Kirn D, Bell JC.

Mol Ther. 2010 May;18(5):888-95. doi: 10.1038/mt.2010.44. Epub 2010 Mar 16.

42.

Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.

Evgin L, Vähä-Koskela M, Rintoul J, Falls T, Le Boeuf F, Barrett JW, Bell JC, Stanford MM.

Mol Ther. 2010 May;18(5):896-902. doi: 10.1038/mt.2010.14. Epub 2010 Feb 16.

43.

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Nguyên TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS, Yasmeen A, Bismar TA, Kirn D, Falls T, Snoulten VE, Vanderhyden BC, Werier J, Atkins H, Vähä-Koskela MJ, Stojdl DF, Bell JC, Hiscott J.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14981-6. doi: 10.1073/pnas.0803988105. Epub 2008 Sep 24.

44.

Modulation of stem cell shape and fate B: mechanical modulation of cell shape and gene expression.

McBride SH, Falls T, Knothe Tate ML.

Tissue Eng Part A. 2008 Sep;14(9):1573-80. doi: 10.1089/ten.tea.2008.0113.

PMID:
18774911
45.

Mechanical modulation of osteochondroprogenitor cell fate.

Knothe Tate ML, Falls TD, McBride SH, Atit R, Knothe UR.

Int J Biochem Cell Biol. 2008;40(12):2720-38. doi: 10.1016/j.biocel.2008.05.011. Epub 2008 May 24. Review.

46.

A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication.

Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H, Bell JC.

Mol Ther. 2008 Aug;16(8):1437-43. doi: 10.1038/mt.2008.130. Epub 2008 Jun 17.

47.

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.

Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, McCart JA, Atkins H, Bell JC.

Mol Ther. 2007 Sep;15(9):1686-93. Epub 2007 Jun 19.

48.

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, Stojdl DF, Forsyth PA, Atkins H, Bell JC.

Mol Ther. 2007 Jan;15(1):123-30.

49.

Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress.

Blais JD, Addison CL, Edge R, Falls T, Zhao H, Wary K, Koumenis C, Harding HP, Ron D, Holcik M, Bell JC.

Mol Cell Biol. 2006 Dec;26(24):9517-32. Epub 2006 Oct 9.

50.

The imperative for controlled mechanical stresses in unraveling cellular mechanisms of mechanotransduction.

Anderson EJ, Falls TD, Sorkin AM, Knothe Tate ML.

Biomed Eng Online. 2006 May 3;5:27.

Supplemental Content

Support Center